We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Eyes Sanofi Antibiotic Over Safety Concerns

Law360 (November 15, 2006, 12:00 AM EST) -- The U.S. Food and Drug Administration has asked a joint panel of outside experts to turn the spotlight on a bronchitis treatment marketed by pharmaceutical giant Sanofi-Aventis SA amid concerns over the antibiotic’s possible link to severe liver problems and several deaths.

The agency said in a federal notice on Tuesday that it wants the panel to discuss the overall risks and benefits of Ketek – also known as also telithromycin – during a meeting on Dec. 14 and 15. The two-day review could result in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.